Advertisement

European Journal of Clinical Pharmacology

, Volume 19, Issue 1, pp 3–10 | Cite as

The regulatory control of non-steroidal anti-inflammatory agents

  • M. N. G. Dukes
  • I. Lunde
Originals

Summary

The number of marketed non-steroidal anti-inflammatory agents varies widely from one European country to another, partly as a consequence of differing regulatory policies. During a four-year period, nine of 18 applications to market such drugs in the Netherlands failed; the remaining nine compounds were all licenced; in all, 22 single drug entities of this type are currently on sale. In Norway during the same period none of the 15 applications received was granted, though five cases are still pending; only seven such drugs are currently licenced for sale. The reasons for the national decisions and for the discrepancies between them are analyzed. A study of the prescribing practice of rheumatologists in the two countries suggests that some 10 to 15 products of this type are in fact needed in order to provide a reasonable choice. Current registration trends could markedly discourage further research investment in this field unless in the near future a basis is found for developing non-steroidal anti-inflammatory drugs with distinct advantages as compared with all those so far known.

Key words

rheumatoid arthritis drug registration non-steroidal anti-inflammatory agents prescribing patterns international comparison 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Valkenburg HA (1979) Frequentie en aard van reumatische aandoeningen in de bevolking. In: Reumatiek en pijnbestrijding. Ciba-Geigy BV, Arnhem, pp. 9–19Google Scholar
  2. 2.
    Dukes MNG, Lunde I (1979) Measuring the repercussions of drug control: an emerging challenge. Pharm J 223: 511–513Google Scholar
  3. 3.
    Dukes MNG, Lunde I (1979) Controls, common sense and communities. Pharm Weekbl 114: 1283–1294Google Scholar
  4. 4.
    Lunde I, Dukes MNG (1980) Les répercussions du contrôle administratif des médicaments (text in French and English). Ind Santé 49: 37–57Google Scholar
  5. 5.
    Ballin JC (1979) Who makes the therapeutic decisions? J Am Med Assoc 242: 2875Google Scholar
  6. 6.
    Jøldal B (1974) Norwegian drug control, organization and tasks. In: Moe M (ed) Report from the Norwegian Drug monopoly. Oslo, pp 32–43 (in Norwegian)Google Scholar
  7. 7.
    Ŝvihovec J (1980) Anti-inflammatory analgesics and drugs used in gout. In: Dukes MNG (ed) Meyler's side effects of drugs, 9th edn. Excerpta Medica, Amsterdam OxfordGoogle Scholar
  8. 8.
    Fenner H (1980) Neue nichtsteroide Antirheumatika — machen sie die Therapie risikoärmer? Dtsch Apoth Ztg 120: 987–992Google Scholar
  9. 9.
    Davies DM (ed) (1977) Textbook of adverse drug reactions. Oxford, p 45Google Scholar
  10. 10.
    Simon LS, Mills JA (1980) New nonsteroidal anti-inflammatory drugs, II. N Engl J Med 302: 1237–1243Google Scholar
  11. 11.
    Steward F, Wibberley G (1980) Drug innovation — what's slowing it down? Nature 284: 118–120Google Scholar
  12. 12.
    Mowat AG (1980) Rheumatoid arthritis. Pharm J 224: 412–416Google Scholar
  13. 13.
    Huskisson EC, Woolf DL, Balme HW, Scott J, Franklyn S (1976) Four new anti-inflammatory drugs: response and variations. Br Med J 2: 1048–1049Google Scholar
  14. 14.
    Gumpel JM (1978) Which anti-inflammatory drugs in rheumatoid arthritis? Br Med J 3: 256Google Scholar
  15. 15.
    Anon. (1977) A.M.A. Drug evaluations. PSG Publishing Comp. Littleton, MA, p 375Google Scholar
  16. 16.
    Hart FD (1980) Rheumatic disorders. In: Avery GS (ed) Drug treatment. Adis Press, Sydney New York, p 864Google Scholar
  17. 17.
    Simonian S, van Gessel HM, Beekhof HG (1980) Carcinogenicity and mutagenicity data on drugs: a retrospective analysis (in press)Google Scholar
  18. 18.
    Bertens AM (1980) Personal communication, based on data available to the Netherlands Council of Health Funds (Ziekenfondsraad)Google Scholar
  19. 19.
    Øydvin K (1978) Legemiddelforbruket i Norge. Norsk Medisinaldepot, OsloGoogle Scholar
  20. 20.
    Vinegar R (1979) Discussion remark cited in: Beers RF, Bassett EG (eds) Mechanisms of pain and analgesic compounds. Raven Press, New York, p 323Google Scholar
  21. 21.
    Løkken P, Skjelbred P (1980) Analgesic and anti-inflammatory effects of paracetamol evaluated by bilateral oral surgery. Br J Clin Pharmacol (in press)Google Scholar
  22. 22.
    Simon LS, Mills JA (1980) Nonsteroidal antiinflammatory drugs I. N Engl J Med 302: 1179–1185Google Scholar
  23. 23.
    Wright V, Amos R (1980) Do drugs change the course of rheumatoid arthritis? Br Med J 2: 964–966Google Scholar
  24. 24.
    Anastassiades TP, Dwosh IL, Ford PM (1980) Progressive rheumatoid arthritis: how far should we go with medical therapy? Can Med Assoc J 122: 1223–1224Google Scholar

Copyright information

© Springer-verlag 1981

Authors and Affiliations

  • M. N. G. Dukes
    • 1
    • 2
  • I. Lunde
    • 1
    • 2
  1. 1.Netherlands Committee for the Evaluation of MedicinesRijswijkThe Netherlands
  2. 2.National Centre for Medicinal Products ControlOsloNorway

Personalised recommendations